Microglia activation mediates fibrillar amyloid-β toxicity in the aged primate cortex

Neurobiology of Aging

Volumn 32, Issue 3, 2011, Pages 387-397

  Leung, Elaine ^a,b   Guo, Ling ^a   Bu, Jing ^a,b   Maloof, Marie ^a,b   Khoury, Joseph El ^c   Geula, Changiz ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyloid toxicity; Fibrillar; Microglia; Neuronal loss; Non human primate

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; FIBRILLAR AMYLOID BETA PROTEIN; MACROPHAGE MIGRATION INHIBITION FACTOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

AGED; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL INTERACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN CELL; INFLAMMATION; MICROGLIA; NEUROBLASTOMA CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RHESUS MONKEY;

AGING; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; CELLS, CULTURED; CEREBRAL CORTEX; FEMALE; HLA-DR ANTIGENS; HUMANS; IMMUNOLOGIC FACTORS; MACACA MULATTA; MICROGLIA; NEURONS; REACTIVE OXYGEN SPECIES; TUFTSIN;

EID: 79952897537     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.02.025     Document Type: Article

References (59)

1. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003, 289:2819-2826.
2. Antic A., Dzenko K.A., Pachter J.S. Engagement of the scavenger receptor is not responsible for beta-amyloid stimulation of monocytes to a neurocytopathic state. Exp. Neurol. 2000, 161:96-101.
3. Barger S.W., Goodwin M.E., Porter M.M., Beggs M.L. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J. Neurochem. 2007, 101:1205-1213.
4. Callahan L.M., Vaules W.A., Coleman P.D. Progressive reduction of synaptophysin message in single neurons in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2002, 61:384-395.
5. Chromy B.A., Nowak R.J., Lambert M.P., Viola K.L., Chang L., Velasco P.T., Jones B.W., Fernandez S.J., Lacor P.N., Horowitz P., Finch C.E., Krafft G.A., Klein W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003, 42:12749-12760.
6. Cillari E., Arcoleo F., Dieli M., D'Agostino R., Gromo G., Leoni F., Milano S. The macrophage-activating tetrapeptide tuftsin induces nitric oxide synthesis and stimulates murine macrophages to kill Leishmania parasites in vitro. Infect. Immun. 1994, 62:2649-2652.
7. Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., Luster A.D., Silverstein S.C., El Khoury J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol. 2002, 160:101-112.
8. Corazza G.R., Zoli G., Ginaldi L., Cancellieri C., Profeta V., Gasbarrini G., Quaglino D. Tuftsin deficiency in AIDS. Lancet 1991, 337:12-13.
9. Davoust N., Vuaillat C., Androdias G., Nataf S. From bone marrow to microglia: barriers and avenues. Trends Immunol. 2008, 29:227-234.
10. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005, 280:17294-17300.
11. El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996, 382:716-719.
12. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
13. El Khoury J.B., Moore K.J., Means T.K., Leung J., Terada K., Toft M., Freeman M.W., Luster A.D. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 2003, 197:1657-1666.
14. Emre M., Geula C., Ransil B.J., Mesulam M.M. The acute neurotoxicity and effects upon cholinergic axons of intracerebrally injected beta-amyloid in the rat brain. Neurobiol. Aging 1992, 13:553-559.
15. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003, 327:128.
16. Geula C., Bu J., Nagykery N., Scinto L.F., Chan J., Joseph J., Parker R., Wu C.K. Loss of calbindin-D28k from aging human cholinergic basal forebrain: relation to neuronal loss. J. Comp. Neurol. 2003, 455:249-259.
17. Geula C., Wu C.-K., Saroff D., Lorenzo A., Yuan M., Yankner B.A. Aging renders the brain vulnerable to amyloid β-protein neurotoxicity. Nat. Med. 1998, 4:827-831.
18. Guilian D., Haverkamp L.J., Yu J.H., Karshin W., Tom D., Li J., Kirkpatrick J., Kuo L.M., Roher A.E. Specific domains of beta-amyloid from Alzheimer's plaque elicit neuron killing in human microglia. J. Neurosci. 1996, 16:6021-6037.
19. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 1999, 38:8972-8980.
20. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999, 19:8876-8884.
21. Hyman B.T., Trojanowski J.Q. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997, 56:1095-1097.
22. Inoue R., Hashimoto K., Harai T., Mori H. NMDA- and beta-amyloid 1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice. J. Neurosci. 2008, 28:14486-14491.
23. Kaul M., Lipton S.A. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8212-8216.
24. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004, 279:46363-46366.
25. Kokovay E., Cunningham L.A. Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol. Dis. 2005, 19:471-478.
26. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
27. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., Finch C.E., Klein W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 2001, 79:595-605.
28. Landi F., Cesari M., Onder G., Russo A., Torre S., Bernabei R. Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am. J. Geriatr. Psychiatry 2003, 11:179-185.
29. Lauckner J., Frey P., Geula C. Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles. Neurobiol. Aging 2003, 24:767-776.
30. Lorenzo A., Yankner B.A. B-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12243-12247.
31. Manelli A.M., Bulfinch L.C., Sullivan P.M., LaDu M.J. Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol. Aging 2006.
32. Meda L., Baron P., Prat E., Scarpini E., Scarlato G., Cassatella M.A., Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25-35]. J. Neuroimmunol. 1999, 93:45-52.
33. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
34. Mochizuki A., Peterson J.W., Mufson E.J., Trapp B.D. Amyloid load and neural elements in Alzheimer's disease and nondemented individuals with high amyloid plaque density. Exp. Neurol. 1996, 142:89-102.
35. Moore K.J., El Khoury J., Medeiros L.A., Terada K., Geula C., Luster A.D., Freeman M.W. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 2002, 277:47373-47379.
36. Najjar V.A. Tuftsin, a natural activator of phagocyte cells: an overview. Ann. N. Y. Acad. Sci. 1983, 419:1-11.
37. Ohm T.G., Muller H., Braak H., Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 1995, 64:209-217.
38. Paresce D.M., Ghosh R.N., Maxfield F.R. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 1996, 17:553-565.
39. Reines S.A., Block G.A., Morris J.C., Liu G., Nessly M.L., Lines C.R., Norman B.A., Baranak C.C. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62:66-71.
40. Rogers J., Lue L.F. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem. Int. 2001, 39:333-340.
41. Rogove A.D., Tsirka S.E. Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr. Biol. 1998, 8:19-25.
42. Rosi S., Vazdarjanova A., Ramirez-Amaya V., Worley P.F., Barnes C.A., Wenk G.L. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience 2006, 142:1303-1315.
43. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N. Y. Acad. Sci. 2000, 924:17-25.
44. Sheng J.G., Mrak R.E., Griffin W.S. Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms. Acta Neuropathol. 1997, 94:1-5.
45. Siemion I.Z., Kluczyk A., Slon J.J., Zimecki M., Wieczorek Z. Immunosuppressive activity of analogs of tripeptide Lys-Arg-Pro with D-amino acid residues. Arch. Immunol. Ther. Exp. (Warsz) 1994, 42:205-207.
46. Simard A.R., Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J. 2004, 18:998-1000.
47. Szkaradkiewicz A. Phagocytosis and microbicidal capacity of human monocytes in the course of HIV infection. Immunol. Lett. 1992, 33:145-150.
48. Terry R.D., Wisniewski H.M. Ultrastructure of senile dementia and of experimental analogues. Aging and the Brain 1972, 89-116. Plenum Press, New York. C.M. Gaitz (Ed.).
49. Thanos S., Mey J., Wild M. Treatment of the adult retina with microglia-suppressing factors retards axotomy-induced neuronal degradation and enhances axonal regeneration in vivo and in vitro. J. Neurosci. 1993, 13:455-466.
50. Trevisani F., Castelli E., Foschi F.G., Parazza M., Loggi E., Bertelli M., Melotti C., Domenicali M., Zoli G., Bernardi M. Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut 2002, 50:707-712.
51. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
52. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J., Hartmann T. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochem. Eur. Arch. Psychiatr. Clin. Neurosci. 1999, 249:291-298.
53. Webster S.D., Galvan M.D., Ferran E., Garzon-Rodriguez W., Glabe C.G., Tenner A.J. Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q. J. Immunol. 2001, 166:7496-7503.
54. Weggen S., Eriksen J.L., Sagi S.A., Pietrzik C.U., Golde T.E., Koo E.H. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. 2003, 278:30748-30754.
55. Weggen S., Eriksen J.L., Sagi S.A., Pietrzik C.U., Ozols V., Fauq A., Golde T.E., Koo E.H. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 2003, 278:31831-31837.
56. Wieczorek Z., Zimecki M., Slon J.J., Siemion I.Z. The immunomodulatory activity of tetra- and tripeptides of tuftsin-kentsin group. Peptides 1994, 15:215-221.
57. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16:921-932.
58. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
59. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59:880-886.